Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Gene therapeutic strategies and relevant clinical trials in neuromuscular disorder in China

Gene Therapy volume 27, pages 321–328 (2020)Cite this article

Subjects

Abstract

Neuromuscular disorder is a diverse group of genetic disease, among which Duchenne muscular dystrophy and Spinal muscular atrophy are most common. Recently, the great breakthroughs of gene targeted therapeutic strategies are leading a profound revolution in the standard care of neuromuscular disorders over the world including China. This review will offer an outline of the molecular pathogenesis, clinical progress, critical trials, as well as the challenges of new gene therapy in the treatment of Spinal muscular atrophy and Duchenne muscular dystrophy in China, mainly includes mRNA splicing modulators and adeno-associated virus mediated gene replacement. We hope to highlight some important findings about the critical development of gene therapy in this field, which might be helpful for suggesting potential therapeutic treatment for neuromuscular disease in China.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Lin Y, Lin CH, Yin X, Zhu L, Yang J, Shen Y, et al. Newborn screening for spinal muscular atrophy in china using DNA mass spectrometry. Front Genet. 2019;10:1255.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Li C, Geng Y, Zhu X, Zhang L, Hong Z, Guo X, et al. The prevalence of spinal muscular atrophy carrier in China: evidences from epidemiological surveys. Medicine (Baltimore). 2020;99:e18975.

    Google Scholar 

  3. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103–15.

    PubMed  Google Scholar 

  4. Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197–207.

    PubMed  Google Scholar 

  5. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93.

    PubMed  Google Scholar 

  6. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177–89.

    CAS  PubMed  Google Scholar 

  7. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155–65.

    CAS  PubMed  Google Scholar 

  8. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371:2120–33.

    PubMed  Google Scholar 

  9. Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14:214–24.

    PubMed  Google Scholar 

  10. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24:1634–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017–26.

    CAS  PubMed  Google Scholar 

  13. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625–35.

    CAS  PubMed  Google Scholar 

  14. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377:1723–32.

    CAS  PubMed  Google Scholar 

  15. De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842–56.

    PubMed  PubMed Central  Google Scholar 

  16. Fyfe I. Long-term benefits of nusinersen in later-onset spinal muscular atrophy. Nat Rev Neurol. 2019;15:368–9.

    PubMed  Google Scholar 

  17. Pane M, Coratti G, Sansone VA, Messina S, Bruno C, Catteruccia M, et al. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data. Ann Neurol. 2019;86:443–51.

    CAS  PubMed  Google Scholar 

  18. Hagenacker T, Wurster CD, Gunther R, Schreiber-Katz O, Osmanovic A, Petri S, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19:317–25.

    CAS  PubMed  Google Scholar 

  19. Poirier A, Weetall M, Heinig K, Bucheli F, Schoenlein K, Alsenz J, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018;6:e00447.

    PubMed  PubMed Central  Google Scholar 

  20. Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, et al. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem. 2018;61:6501–17.

    CAS  PubMed  Google Scholar 

  21. Sturm S, Gunther A, Jaber B, Jordan P, Al Kotbi N, Parkar N, et al. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019;85:181–93.

    CAS  PubMed  Google Scholar 

  22. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713–22.

    CAS  PubMed  Google Scholar 

  23. Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54:179–85.

    PubMed  Google Scholar 

  24. Al-Zaidy SA, Kolb SJ, Lowes L, Alfano LN, Shell R, Church KR, et al. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. J Neuromuscul Dis. 2019;6:307–17.

    PubMed  Google Scholar 

  25. Mercuri E, Bonnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394:2025–38.

    PubMed  Google Scholar 

  26. Li X, Zhao L, Zhou S, Hu C, Shi Y, Shi W, et al. A comprehensive database of Duchenne and Becker muscular dystrophy patients (0-18 years old) in East China. Orphanet J Rare Dis. 2015;10:5.

    PubMed  PubMed Central  Google Scholar 

  27. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat. 2009;30:293–9.

    PubMed  Google Scholar 

  28. Rodrigues M, Yokota T. An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases. Methods Mol Biol. 2018;1828:31–55.

    CAS  PubMed  Google Scholar 

  29. Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637–47.

    CAS  PubMed  Google Scholar 

  31. Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, et al. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production. Neurology. 2018;90:e2146–e54.

    CAS  PubMed  Google Scholar 

  32. Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79:257–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Khan N, Eliopoulos H, Han L, Kinane TB, Lowes LP, Mendell JR, et al. Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with duchenne muscular dystrophy. J Neuromuscul Dis. 2019;6:213–25.

    PubMed  PubMed Central  Google Scholar 

  34. Kinane TB, Mayer OH, Duda PW, Lowes LP, Moody SL, Mendell JR. Long-term pulmonary function in duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. J Neuromuscul Dis. 2018;5:47–58.

    PubMed  PubMed Central  Google Scholar 

  35. Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94:2270–82.

    Google Scholar 

  36. Aartsma-Rus A, Corey DR. The 10th oligonucleotide therapy approved: golodirsen for duchenne muscular dystrophy. Nucleic Acid Ther. 2020;30:67–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Heo YA. Golodirsen: first approval. Drugs. 2020;80:329–33.

    PubMed  Google Scholar 

  38. Dent KM, Dunn DM, von Niederhausern AC, Aoyagi AT, Kerr L, Bromberg MB, et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A. 2005;134:295–8.

    CAS  PubMed  Google Scholar 

  39. Guo R, Zhu G, Zhu H, Ma R, Peng Y, Liang D, et al. DMD mutation spectrum analysis in 613 Chinese patients with dystrophinopathy. J Hum Genet. 2015;60:435–42.

    CAS  PubMed  Google Scholar 

  40. Finkel RS, Flanigan KM, Wong B, Bonnemann C, Sampson J, Sweeney HL, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS ONE. 2013;8:e81302.

    PubMed  PubMed Central  Google Scholar 

  41. Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50:477–87.

    CAS  PubMed  Google Scholar 

  42. McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1489–98.

    CAS  PubMed  Google Scholar 

  43. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. 2012;20:443–55.

    CAS  PubMed  Google Scholar 

  44. Duan D. Systemic AAV Micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol Ther. 2018;26:2337–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy Type 1. Adv Ther. 2019;36:1164–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7:1601484.

    PubMed  PubMed Central  Google Scholar 

  47. Lee J, Echigoya Y, Duddy W, Saito T, Aoki Y, Takeda S, et al. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts. PLoS ONE. 2018;13:e0197084.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Department, Children’s Hospital of Fudan University, NO.399 Wanyuan Road, Shanghai, China

    Chaoping Hu & Xihua Li

Authors
  1. Chaoping Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xihua Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xihua Li.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, C., Li, X. Gene therapeutic strategies and relevant clinical trials in neuromuscular disorder in China. Gene Ther 27, 321–328 (2020). https://doi.org/10.1038/s41434-020-0158-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41434-020-0158-4

This article is cited by

Search

Advanced search

Quick links